Table 1.

Comparison of rituximab sensitivity with CD20, −55, −59 surface expression in lymphoblastoid and lymphoma cell lines.

Cell line	Viabilitya	CD20b	CD55b	CD59b
	rituximab, (n = 10)	LCLs (n = 4)	(n = 1)	(n = 1)
		Lymphomas (n = 2)
12622	0.28 ± 0.028	53 ± 8.4	205	134
11828	0.31 ± 0.004	28 ± 3.7	130	221
12621	0.32 ± 0.004	41 ± 9.8	254	185
12828	0.37 ± 0.031	22 ± 3.0	232	229
12754	0.64 ± 0.064	34 ± 4.5	48	273
12803	0.88 ± 0.009	20 ± 2.6	210	189
12698	0.93 ± 0.019	8 ± 0.1	104	170
11988	0.90 ± 0.036	13 ± 3.2	167	244
11989	1.00 ± 0.012	24 ± 5.1	114	119
10839	1.03 ± 0.013	19 ± 2.6	217	207
Daudi	0.17 ± 0.028	85 ± 15.0	57	175
Raji	0.24 ± 0.052	50 ± 5.0	38	61
BJAB	0.49 ± 0.089	77 ± 1.8	19	8
SUDHL4	0.28 ± 0.023	67 ± 50	29	16
HT	0.57 ± 0.045	81 ± 1.0	198	382
Farage	0.74 ± 0.039	131 ± 78	21	69
DB	0.77 ± 0.021	118 ± 10	29	44
SUDHL10	0.83 ± 0.036	62 ± 53	19	7

Notes.

^aViability is represented as a ratio of growth with/without 10 µg/ml of rituximab in the presence of 25% human serum and expressed as an average ±SEM. Cell lines are grouped as: CEPH lines or lymphoma lines and listed from most sensitive to most resistant based on results from viability assays conducted in the presence of rituximab and human serum. Median viability of LCLs was 0.77 and the bold line separates “sensitive” (above) and “resistant” (below) LCLs.

^bCD −20, −55, and −59 surface expression is represented as relative median fluorescence.